Celsius Therapeutics harnesses artificial intelligence and single-cell genomics for the discovery and development of precision medicines for complex diseases.
Founded in 2018, Celsius Therapeutics is a biotechnology company focused on leveraging AI-driven data science and single-cell RNA sequencing to unlock the mysteries of immune-mediated diseases and cancer. By applying cutting-edge computational biology, Celsius enables high-resolution analysis of cellular processes, accelerating the development of targeted therapies with the potential to transform patient outcomes.
competitors.competitorDetail.metrics.missionStatement
To decode disease biology and develop transformative precision medicines through AI and single-cell genomics.
competitors.competitorDetail.metrics.visionStatement
To set a new standard in personalized medicine by unlocking the potential of every patient's unique biology.
competitors.competitorDetail.metrics.foundedYear
2018
competitors.competitorDetail.metrics.ceo
Tariq Kassum
competitors.competitorDetail.metrics.employees
50-100
competitors.competitorDetail.metrics.revenue
$10M - $25M
competitors.competitorDetail.metrics.headquarters
201 Brookline Street, Cambridge, MA 02139, USA
competitors.competitorDetail.metrics.marketShare
<1% in global precision medicine R&D, growing presence in AI-biotech segment
competitors.competitorDetail.metrics.usp
Integrates state-of-the-art AI with single-cell genomics to drive novel target discovery and drug development.
competitors.competitorDetail.metrics.pricingModel
B2B partnerships, research collaborations, licensing agreements, milestone and royalty-based
- Autoimmunity Therapeutics
- Oncology Therapeutics
- AI Discovery Platform
- Python
- TensorFlow
- Single-cell RNA seq platforms
- Custom ML pipelines
- Cloud Computing (AWS)
competitors.competitorDetail.metrics.marketPositioning
Innovative disruptor in the AI-driven drug discovery and precision medicine space.
- Pharmaceutical R&D departments
- Academic research institutions
- Precision medicine innovators
- Direct partnerships with pharmaceutical companies
- Academic collaborations
- Industry consortiums
- Scientific publications and conference presentations
- Direct engagement with pharma R&D leaders
- Presence in major biotech and health innovation events
- Thought leadership in AI/genomics healthcare forums
- Parker Institute for Cancer Immunotherapy (Research Collaboration)
- Third Rock Ventures (Lead Investor)
- Alexandria Venture Investments (Investor)
- Single-cell RNA sequencing analytics
- AI-powered target identification
- Precision medicine pipeline
- Collaborative scientific ecosystem
- Proprietary AI/ML pipelines for single-cell data analysis
- Extensive scientific leadership with industry and academic pedigree
- Strong partnerships with academic and pharma organizations
- Robust pipeline of high-potential therapeutics for autoimmunity and oncology
- Long R&D timelines typical in biotech
- High capital requirements for clinical development
- Success dependent on regulatory approvals and clinical trial outcomes
- Expansion into additional disease areas using their platform
- Strategic collaborations with pharmaceutical companies
- Advancements in AI and genomics technologies
- Competitive landscape in AI-driven drug discovery
- Potential clinical trial setbacks
- Rapidly evolving regulatory environment for genomics and AI
competitors.competitorDetail.metrics.growthRateYOY
35%-40%
competitors.competitorDetail.metrics.profitMargin
Pre-revenue; funded through investment and licensing deals
competitors.competitorDetail.metrics.customerAcquisitionCost
Primarily relationship and scientific value-based (N/A for product sales)
competitors.competitorDetail.metrics.customerLifetimeValue
High (multi-million via partnerships and milestone payments)
competitors.competitorDetail.metrics.churnRate
Very low (long-term collaborations)
| competitors.competitorDetail.metrics.fundingStage | competitors.competitorDetail.metrics.fundingAmount | competitors.competitorDetail.metrics.fundingDate |
|---|---|---|
| Series A | $65M | 2018-05-21 |
| Series B | $83M | 2021-09-14 |
- Mission-driven with patient-centric focus
- Collaborative, high-achieving scientific culture
- Diversity in research background and expertise
- Commitment to discovery and integrity
- FierceBiotech 'Fierce 15' (2020) - FierceBiotech
- Endpoints 11 Emerging Biotechs (2022) - Endpoints News
| competitors.competitorDetail.reviews.title | competitors.competitorDetail.reviews.rating | competitors.competitorDetail.reviews.viewAll |
|---|---|---|
| BioCentury | 4.8/5 | 10 |
| competitors.competitorDetail.news.title | competitors.competitorDetail.news.publishedOn | competitors.competitorDetail.news.readMore |
|---|---|---|
| Celsius Therapeutics Raises $83M in Series B to Advance Pipeline | 2021-09-14 | Fierce Biotech |
| Celsius and Parker Institute Announce Immunotherapy Collaboration | 2023-07-20 | Endpoints News |